Amryt Pharma plc logo
Amryt Pharma plc AMYT

Annual report 2021
added 12-23-2023

report update icon

Amryt Pharma plc Net Debt 2011-2026 | AMYT

Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]

Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.

Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.

Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.

Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.

Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.

Annual Net Debt Amryt Pharma plc

2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
- 70.6 M 112 M 7.78 M -11.2 M -8.7 M -16.8 M -17.4 M -31.5 M -239 K -1.61 K

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
112 M -31.5 M 10.4 M

References

  1. Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.

Net Debt of other stocks in the Biotechnology industry

Issuer Net Debt Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
163 M - 2.43 % $ 254 M germanyGermany
ARCA biopharma ARCA biopharma
ABIO
-60.6 M - 1052.0 % $ 415 M usaUSA
Processa Pharmaceuticals Processa Pharmaceuticals
PCSA
-4.56 M $ 2.3 -1.29 % $ 3.01 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
-65.1 M - 5.93 % $ 314 M canadaCanada
Albireo Pharma Albireo Pharma
ALBO
-239 M - -0.23 % $ 916 M usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
-3.44 M - 10.36 % $ 9.8 M usaUSA
I-Mab I-Mab
IMAB
-1.06 B - - $ 866 M chinaChina
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
-402 M - - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
2.27 M - 2.54 % $ 160 B franceFrance
Biophytis SA Biophytis SA
BPTS
-4.01 M - -13.47 % $ 169 M franceFrance
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
-195 M $ 220.9 2.49 % $ 5 B danmarkDanmark
Aptinyx Aptinyx
APTX
-33.8 M - -39.0 % $ 4.57 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
-6.17 M - -18.52 % $ 27.3 M britainBritain
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
-824 K - -1.52 % $ 24.7 M usaUSA
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
457 M $ 19.57 1.77 % $ 915 M usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
-36 M - - $ 26.5 M usaUSA
Phathom Pharmaceuticals Phathom Pharmaceuticals
PHAT
79.8 M $ 10.47 4.08 % $ 763 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
-657 K - - $ 7.46 M israelIsrael
AgeX Therapeutics AgeX Therapeutics
AGE
12.6 M - -10.17 % $ 12.2 K usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
114 M - -24.86 % $ 820 K usaUSA
Atreca Atreca
BCEL
33.1 M - -11.76 % $ 5.79 M usaUSA
Acasti Pharma Acasti Pharma
ACST
-27.4 M - 4.01 % $ 150 M canadaCanada
BeiGene, Ltd. BeiGene, Ltd.
BGNE
-3.56 B - 0.49 % $ 251 B cayman-islandsCayman-islands
bluebird bio bluebird bio
BLUE
-163 M - - $ 546 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
246 M - - - russiaRussia
Cara Therapeutics Cara Therapeutics
CARA
-9.78 M - -3.03 % $ 260 M usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
31.1 M - - $ 86.2 M usaUSA
Acer Therapeutics Acer Therapeutics
ACER
-2.08 M - 2.71 % $ 14 M usaUSA
Advaxis Advaxis
ADXS
3.42 M - -9.65 % $ 45.9 M usaUSA
Pliant Therapeutics Pliant Therapeutics
PLRX
-40.4 M $ 1.31 2.34 % $ 80.4 M usaUSA
PMV Pharmaceuticals PMV Pharmaceuticals
PMVP
-37.1 M $ 1.37 -1.44 % $ 72 M usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
-3.13 K - -52.27 % $ 4.45 M usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
-187 M $ 1.33 0.76 % $ 339 M britainBritain
Corbus Pharmaceuticals Holdings Corbus Pharmaceuticals Holdings
CRBP
263 K $ 8.31 1.59 % $ 111 M usaUSA
CRISPR Therapeutics AG CRISPR Therapeutics AG
CRSP
-141 M $ 47.09 1.42 % $ 4.23 B schweizSchweiz
Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals
CYCC
-3.34 M - -5.98 % $ 34.1 M usaUSA
ChemoCentryx ChemoCentryx
CCXI
-42.5 M - - $ 3.74 B usaUSA
Prelude Therapeutics Incorporated Prelude Therapeutics Incorporated
PRLD
-17.5 M $ 3.26 4.49 % $ 251 M usaUSA
Dynavax Technologies Corporation Dynavax Technologies Corporation
DVAX
-65.3 M - - $ 2.02 B usaUSA
ProQR Therapeutics N.V. ProQR Therapeutics N.V.
PRQR
-171 M $ 1.58 6.04 % $ 99.5 M niderlandNiderland
BioDelivery Sciences International BioDelivery Sciences International
BDSI
-33.1 M - -4.8 % $ 255 M usaUSA
Enochian Biosciences Enochian Biosciences
ENOB
645 K - - $ 40.5 M usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
-30.2 M - - $ 1.01 B usaUSA
CureVac N.V. CureVac N.V.
CVAC
-783 M - - $ 867 M germanyGermany
Palatin Technologies Palatin Technologies
PTN
-2.4 M $ 21.0 5.79 % $ 19.5 M usaUSA
Bellerophon Therapeutics Bellerophon Therapeutics
BLPH
-23.8 M - -74.18 % $ 955 K usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
-340 M - - $ 3.67 B usaUSA
Pulmatrix Pulmatrix
PULM
-51.6 M $ 2.12 -1.4 % $ 7.74 M usaUSA
Arbutus Biopharma Corporation Arbutus Biopharma Corporation
ABUS
-107 M $ 4.53 5.1 % $ 868 M canadaCanada
Homology Medicines Homology Medicines
FIXX
-42.7 M - 0.77 % $ 53.4 M usaUSA